Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAD induction followed by MEL100 transplant in elderly newly diagnosed multiple myeloma
2005-004714-32Phase 2Active
- Sponsor
- Fondazione EMN Italy
- Start
- Dec 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, doxorubicin, dexamethasone and melphalan in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoint: Safety and clinical benefit of PAD-MEL100 sequence. Started Dec 2007; status: active.
02
Drugs
bortezomibdoxorubicindexamethasonemelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-004714-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004714-32.